通过大数据揭示乳腺癌中的药物基因组模式
Huiyi Yang1, Joseph Finkelstein1
1University of Utah.
Studies in health technology and informatics
|August 8, 2025
概括
药物基因组学 (PGx) 影响癌症治疗. 许多乳腺癌患者具有影响药物代谢的遗传变异,这凸显了个性化医疗方法的必要性.
科学领域:
- 基因组学就是基因组学.
- 在瘤学瘤学.
- 个性化医疗是个性化的医疗.
背景情况:
- 药物基因组学 (PGx) 对于个性化医疗在癌症治疗中至关重要.
- 遗传变异会影响药物的疗效和毒性.
- 酶CYP2D6的活性是许多常见药物的代谢的关键.
研究的目的:
- 在女性乳腺癌患者中调查与CYP2D6相关的药物和表型的流行率.
- 评估遗传变异对该队列药物反应的影响.
- 评估药物基因组数据在乳腺癌治疗中的临床实用性.
主要方法:
- 利用了5576名女性乳腺癌患者的基因组和电子健康记录 (EHR) 数据,用于NIH的"我们所有人"研究计划.
- 开发了一个定制的管道来确定CYP2D6的基因型和表型.
- 分析了CYP2D6代谢药物的处方数据,包括塔莫西芬,丹塞和特拉马多尔.
主要成果:
- 77%的患者被处方至少一种CYP2D6代谢的药物.
- 在12.5%的队列中确定了可操作的CYP2D6表型.
- 大约25%的表型患者表现出非正常的代谢器类型,诊断后处方增加.
结论:
- 在乳腺癌患者中,CYP2D6相关药物和非正常代谢器表型的显著流行.
- 强调药物基因组学考虑对于优化治疗的重要性.
- 支持将PGx指南整合到常规临床实践中,以改善患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Analysis of Population Pharmacokinetic Data
385
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
385
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
126
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
126


